Welcome to our dedicated page for Branded Legacy news (Ticker: BLEG), a resource for investors and traders seeking the latest updates and insights on Branded Legacy stock.
Stay informed about developments from Branded Legacy Inc, a pharmaceutical biotechnology company focused on intranasal drug delivery innovation. The company operates through its Bio-Legacy Evaluative Group subsidiary, developing air-driven intranasal devices for therapeutic applications.
News coverage for Branded Legacy typically includes updates on regulatory milestones, clinical development progress, partnership announcements with academic institutions, manufacturing developments at GMP facilities, and intellectual property filings related to the company's intranasal delivery platform.
The company's primary development program focuses on intranasal naloxone for opioid overdose reversal, pursuing FDA approval through the abbreviated new drug application pathway. Investors monitor announcements regarding Pre-ANDA meetings, bioequivalence study designs, manufacturing prototyping, and regulatory submission timelines.
Following a significant management restructuring and strategic reset, the company divested all legacy hemp and CBD subsidiaries to focus exclusively on pharmaceutical development. News may cover the company's transition from consumer wellness products to FDA-regulated pharmaceutical innovation.
Corporate announcements may include management changes, strategic partnerships, financing activities, manufacturing agreements, and updates on the company's intellectual property portfolio. The company operates in the specialty pharmaceutical sector, competing in the growing naloxone market driven by public health initiatives addressing opioid overdose prevention.
Market news often discusses broader trends in addiction medicine, opioid crisis developments, naloxone accessibility programs, regulatory changes affecting naloxone distribution, and competitive dynamics among companies developing alternative formulations or delivery methods for overdose reversal medications.
Branded Legacy (OTC:BLEG) announced the successful retirement of approximately $1 million in legacy convertible debt that originated under prior management. New leadership completed due diligence, negotiated directly with note holders, and retired the convertible instruments on reportedly favorable terms.
The company says the transaction removes associated liabilities, substantially reduces future dilution risk, and improves financial flexibility. Management is updating its issuer profile with OTC Markets Group and is focused on satisfying remaining requirements to remove the OTC Yield Sign from the ticker to improve transparency and accessibility for shareholders.
Branded Legacy (OTC:BLEG) announced a change of control effective Dec 10, 2025 after shareholder Dr. Jamie Forrest acquired the controlling interest and removed all prior officers and directors.
The company says it has divested all legacy subsidiaries, will perform a forensic review of historical issuances, and expects conversion of pre-existing convertible instruments totaling approximately 300 million shares. Management plans a clean restart with a new operating business, stricter disclosure discipline, and an updated OTCMarkets profile aimed at removing the current Yield Sign.
Branded Legacy (OTC:BLEG) announced that its newly acquired subsidiary Pau Hana reported third-quarter revenue of $125,000 and will be scaled via a roll-up strategy targeting additional cash-flow-positive kava bar locations.
The company plans to open 3–5 new Florida locations in 2026, aims to grow Pau Hana's footprint by 150% within the year, and will apply centralized sourcing, branding, and operations to improve margins. Pau Hana opened in January 2023 in West Melbourne, Florida, and generates daily retail income from kava sales, mocktails, events, and merchandise. Branded Legacy also said its BioLegacy Evaluative Group began development of a mold for a single-use intranasal delivery device tied to its inhaled naloxone program.
Branded Legacy (OTC:BLEG) announced on October 27, 2025 that subsidiary BioLegacy Evaluative Group initiated engineering and development of a unitary device mold for its air-driven intranasal drug delivery platform.
The milestone advances scalable production of a single-use device intended for rapid, consistent delivery of therapeutics, including an inhaled naloxone program, and aligns with the company’s User Requirements Specification (URS). The work follows a provisional patent filing in September 2025 and complements a GMP-compliant manufacturing facility opened September 23, 2025 in Vancouver to support high-volume, cost-effective manufacturing for global pharmaceutical standards.
Branded Legacy (OTC: BLEG) said its subsidiary BioLegacy Evaluative Group has begun preparing an FDA Pre-ANDA briefing package for a proprietary air-driven intranasal naloxone spray aimed at treating acute opioid overdose. Key dossier elements include 2 mg and 4 mg naloxone HCl nasal-spray Target Product Profiles with a targeted 18–36 month shelf life, draft CMC work aligned with ICH guidance, a pivotal 60-subject crossover PK bioequivalence study versus Narcan measuring Cmax/AUC/Tmax, and a 20–30 participant device human-factors usability study with a <5% critical-error target.
BioLegacy will request FDA guidance on whether a single pivotal PK study suffices, human-factors validation expectations, and extractables/leachables testing for its custom unitary device. The company cites a provisional patent for the platform and its GMP manufacturing facility to support development and regulatory submissions.
Branded Legacy (OTC:BLEG) announced that its subsidiary BioLegacy has filed a provisional patent for an innovative air-driven intranasal drug delivery platform. The technology features a thumb-sized, single-use device that delivers precise intranasal dosing for both stable liquid formulations and drugs requiring reconstitution.
The platform's key innovations include an air-driven precision delivery system, dual-function architecture, unitary blow-fill-seal construction, and sequential frangible membranes. The device is specifically designed to improve the delivery of medications like naloxone for opioid overdose reversal, targeting enhanced accessibility and affordability in emergency scenarios.
The development aligns with BioLegacy's recent acquisition of a GMP-compliant manufacturing facility with ISO Class 7 & 8 cleanrooms, and ongoing R&D collaborations with McMaster University and Stanford University.
Branded Legacy (OTC: BLEG) has unveiled a new 22,000-square-foot GMP facility in Vancouver, Canada, dedicated to developing innovative inhaled naloxone devices for opioid overdose treatment. The state-of-the-art facility features advanced ISO Class 7 & 8 cleanrooms, high-containment capabilities, and integrated laboratory systems.
The facility represents a significant milestone following BLEG's acquisition of BioLegacy Evaluative Group and partnerships with McMaster University and Stanford University. Led by CEO Amin Janmohamed and Executive Chair Dr. Kristian Thorlund, the company aims to accelerate the development of affordable overdose-reversal solutions while maintaining potential for future expansion into vaccine delivery and other medications.
Branded Legacy (OTC: BLEG) has acquired a 22,000-square-foot GMP facility in Vancouver, Canada through its subsidiary BioLegacy Evaluative Group. The state-of-the-art facility features ISO Class 7 and 8 clean rooms equipped to handle opioids and controlled substances, positioning the company to develop addiction treatment and harm reduction solutions.
The strategic acquisition builds upon BLEG's partnerships with McMaster University and Stanford University for addiction treatment research. Located in Vancouver's drug crisis epicenter, the facility will enable direct collaboration with affected populations. The company has pending applications with Health Canada for Controlled Substances Licenses to ensure regulatory compliance.
Branded Legacy (OTC: BLEG) has announced a strategic partnership with Stanford University's Dr. Eran Bendavid to advance addiction treatment solutions. The collaboration integrates Stanford's AI-powered systematic review platform for rapid evidence synthesis with BLEG's drug development initiatives, particularly focusing on intranasal naloxone development.
This partnership follows BLEG's recent acquisition of Bio-Legacy Evaluative Group and collaboration with McMaster University. The company aims to leverage Dr. Bendavid's expertise in global health and policy analysis to optimize its product strategy in the naloxone market, which is projected to grow from $371 million in 2022 to $1.16 billion by 2032 at a CAGR of 11.9%.
Branded Legacy (OTC: BLEG) has announced a strategic partnership between its subsidiary, Bio-Legacy Evaluative Group, and McMaster University to advance addiction treatment research and development. The collaboration focuses on evaluating Bio-Legacy's innovative products, including their flagship patented intranasal naloxone delivery device.
The partnership leverages McMaster's clinical research expertise and Bio-Legacy's real-world experience to conduct multiple clinical trials and regulatory submissions. Their primary focus is developing accessible, cost-effective interventions for overdose prevention and addiction treatment. The initiative targets the naloxone market, projected to grow from $371 million (2022) to $1.16 billion by 2032, with a CAGR of 11.9%.
FAQ
What is the current stock price of Branded Legacy (BLEG)?
What is the market cap of Branded Legacy (BLEG)?
